Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keenova Therapeutics plcMNK · Entity 28960 | Chief Compliance Officer | January 04, 2017 | January 06, 2017 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | EVP, GC, CCO & Corp Sec | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keenova Therapeutics plc
Report date January 04, 2017 · Filed January 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 6,462 |
Reported balance
After 2017-01-04 transaction · row 1
1 source rowRow 1 · 2017-01-04 · Tax withholding · Disposed 242 · Balance 6,462 |
RIGEL PHARMACEUTICALS INC
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,559 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Tax withholding · Disposed 877 · Balance 50,559 F1: Includes 500 shares acquired under the Issuer's stock purchase plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 500 shares acquired under the Issuer's stock purchase plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 22:59 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 877 | $47.50 | $41,657.50 |
DisclosureSEC source: 0000905148-26-004077 · form4.xml · nonDerivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,559 F1 · balance_after: Includes 500 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:12 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 7,394 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-26-003039 · form4.xml · derivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,394 Underlying: Common Stock · 7,394 shares Expires 2035-01-29 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:01 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 877 | $29.86 | $26,187.22 |
DisclosureSEC source: 0000905148-26-002807 · form4.xml · nonDerivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,936 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 19,497 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000956 · form4.xml · nonDerivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,813 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 3,546 | $34.62 | $122,762.52 |
DisclosureSEC source: 0000905148-26-000676 · form4.xml · nonDerivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,316 Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 3,968 | $36.01 | $142,887.68 |
DisclosureSEC source: 0000905148-26-000496 · form4.xml · nonDerivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,862 F1 · balance_after: Includes 1,000 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 7,394 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-25-003348 · form4.xml · derivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,394 Underlying: Common Stock · 7,394 shares Expires 2035-01-29 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 00:55 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 7,850 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000905148-25-000976 · form4.xml · derivative · entry 2 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,850 Underlying: Common Stock · 7,850 shares Expires 2034-01-23 F3 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F3 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met. F3 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 00:55 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 9,375 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000976 · form4.xml · derivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires 2032-12-08 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 01:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 1,339 | $21.93 | $29,358.91 |
DisclosureSEC source: 0000905148-25-000410 · form4.xml · nonDerivative · entry 2 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,830 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 04, 2025 Filed Feb 7, 2025 01:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 1,448 | $20.92 | $30,293.61 |
DisclosureSEC source: 0000905148-25-000410 · form4.xml · nonDerivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,169 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,788 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-25-000298 · form4.xml · derivative · entry 2 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,788 Underlying: Common Stock · 14,788 shares Expires 2035-01-29 F4 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 19,717 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000298 · form4.xml · nonDerivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,617 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026. F2 · balance_after: This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F3 · balance_after: Includes 500 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 00:14 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 78,500 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000905148-24-000848 · form4.xml · derivative · entry 2 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,500 Underlying: Common Stock · 78,500 shares Expires 2034-01-23 F2 · shares: The Reporting Person was granted an option with a performance-based condition with respect to 78,500 shares of the issuer's common stock on January 23, 2024. Thus, the exercise price of this option is $1.27 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met. F3 · derivative.exercise_date: The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 00:14 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 93,750 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000905148-24-000848 · form4.xml · derivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2032-12-08 F1 · shares: The Reporting Person was granted an option with a performance-based condition with respect to 93,750 shares of the issuer's common stock on December 8, 2022. Thus, the exercise price of this option is $0.8965 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met. F3 · derivative.exercise_date: The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 02:17 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 157,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000905148-24-000309 · form4.xml · derivative · entry 2 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,000 Underlying: Common Stock · 157,000 shares Expires 2034-01-23 F3 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 02:17 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 209,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000309 · form4.xml · nonDerivative · entry 1 Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,000 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 1, 2024, with the first annual vest occurring on February 1, 2025. F2 · balance_after: Includes 5,000 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 23:06 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 242 | $53.19 | $12,871.98 |
DisclosureSEC source: 0000950138-17-000047 · edgar.xml · nonDerivative · entry 1 Furey Raymond J. · CIK 0001577899 · Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,462 Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 02:17 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 102 | $49.82 | $5,081.64 |
DisclosureSEC source: 0000950138-17-000024 · edgar.xml · nonDerivative · entry 1 Furey Raymond J. · CIK 0001577899 · Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,704 F1 · balance_after: Includes 569 shares acquired between January 7, 2016 and September 30, 2016 under the Mallinckrodt employee stock purchase plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.